Bakiye Göker Bağca, Çığır Biray Avcı

Ege Üniversitesi Tıp Fakültesi Tıbbi Biyoloji Anabilim Dalı, İzmir, Türkiye

Keywords: Mechanisms; myeloproliferative neoplasm’s; ruxolitinib.


Ruxolitinib is the inhibitor of JAK1 and JAK2 tyrosine kinases. Known as Jakafi, ruxolitinib is the first approved chemical agent for myelofibrosis treat- ment which has been used since 2011. Myeloproliferative neoplasms (MPN) include Philedalphia chromosome (Ph) positive and negative disorders. Since the development of imatinib in 2001, treatment of Ph+ chronic myeloid leukemia has focused on tyrosine kinase inhibitors. New generation tyrosine kinase inhibitors were improved and used depending on development of resistance. On the contrary, targeted therapy in Ph- MPNs is a con- temporary topic that is less discovered. MPNs usually arise from mutations in JAK-STAT pathway. In this review, we analyze targeted therapy options via ruxolitinib as the most current tyrosine kinase inhibitor for both Ph+ and Ph- myeloproliferative neoplasms.